Price$20.17-1.02 (-4.81%)
01:30 PM07:45 PM
News · 26 weeks41-64%
2025-12-142026-06-07
Mix2690d
- SEC Filings12(46%)
- Insider8(31%)
- Other6(23%)
Latest news
25 items- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- PRGH Research Announces Publication of Phase 2a Postpartum Depression ResultsDUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World Congress of Neuropsychopharmacology (CINP 2026). The peer-reviewed article, titled "Inhaled Mebufotenin (GH001) for Adult Patients with Postpartum Depression: A Phase 2a Open-Label Clinical Trial," has been published in The Journal of Clinical Psychiatry (DOI: 10.4088/JCP.25m16284). The article reports the full results from the Phase 2a, single-arm, open-label trial, which enrolled 10 adult women with PPD. Key results: Primary endpoint met: Mean Mont
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- SECSEC Form EFFECT filed by GH Research PLCEFFECT - GH Research PLC (0001855129) (Filer)
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- SECSEC Form F-3 filed by GH Research PLCF-3 - GH Research PLC (0001855129) (Filer)
- SECSEC Form 424B5 filed by GH Research PLC424B5 - GH Research PLC (0001855129) (Filer)
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- PRGH Research Reports First Quarter 2026 Financial Results and Provides Business UpdatePhase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash, cash equivalents and marketable securities of $267.3 million as of March 31, 2026Net cash proceeds of an additional $111.2 million from underwritten offering received in April 2026 DUBLIN, May 14, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended March 31, 2026, and
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- SECSEC Form 424B5 filed by GH Research PLC424B5 - GH Research PLC (0001855129) (Filer)
- PRGH Research Announces Pricing of $117.5 Million Underwritten OfferingDUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United States of 6,527,779 of its ordinary shares at an offering price of $18.00 per share for total gross proceeds of approximately $117.5 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on April 30, 2026, subject to customary closing conditions. The offering was initia
- PRGH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental IllnessDUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today issued a statement welcoming the White House Executive Order, signed on April 18, 2026, to accelerate medical treatments for serious mental illness, including innovative psychedelic medical treatments (the Executive Order). The Executive Order directs coordinated federal action to accelerate the development of, and expand patient access to, innovative therapies for serious mental illness. GH Research continues to advance GH001, its proprietary inhaled mebufotenin
- INSIDERSEC Form 3 filed by new insider Moore Duncan3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cameron Aaron Luke3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hanley Dermot John3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Halle Magnus Clemensen3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Forer Michael3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Valcheva Velichka3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ryan Julie3 - GH Research PLC (0001855129) (Issuer)
- INSIDERSEC Form 3 filed by new insider Schonharting Florian3 - GH Research PLC (0001855129) (Issuer)
- SECSEC Form 6-K filed by GH Research PLC6-K - GH Research PLC (0001855129) (Filer)
- PRGH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDPhase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior antidepressant treatment failures DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that eff
GHRS FAQ
7 questionsWhat does GH Research PLC do?
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical...Where does GHRS stock trade?
GH Research PLC (GHRS) is listed on NASDAQ.What sector and industry is GHRS in?
GH Research PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did GH Research PLC go public?
GH Research PLC (GHRS) completed its IPO in 2021.What are analysts saying about GHRS?
GH Research PLC has had 8 recent analyst actions on file. The most recent action was from Needham: Buy with a $1900.00 price target on 2025-10-13. Recent price targets range from $1400.00 to $4500.00.What companies are similar to GHRS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GHRS side-by-side with any of them on Quantisnow.How can I track GHRS on Quantisnow?
Quantisnow aggregates GH Research PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GHRS to receive live email and push alerts on every new disclosure.